Trials / Completed
CompletedNCT02654522
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Steve Yoelin M.D. Medical Associates, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether or not Recombinant DNA-based hyaluronidase (RDNAH/Hylenex recombinant), is safe and effective for dissolving hyaluronic acid (HA) dermal fillers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hylenex | 1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U). |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2016-01-13
- Last updated
- 2017-05-16
Source: ClinicalTrials.gov record NCT02654522. Inclusion in this directory is not an endorsement.